<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess plasmapheresis with low dose <z:chebi fb="0" ids="8382">prednisone</z:chebi> on obstetric and neonatal outcomes among unsuccessfully treated pregnant women with documented <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Eighteen pregnant women received <z:chebi fb="0" ids="8382">prednisone</z:chebi> (10 mg/day) and plasmapheresis at 7.08+/-0.6 weeks of gestation, for 3 sessions per week, until <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity suppressed and IgG anticardiolipin lowered </plain></SENT>
<SENT sid="2" pm="."><plain>Serial pulsatility indexes (PI) of umbilical and uterine arteries were performed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The live birth rate was 100%; mild pre-<z:hpo ids='HP_0100601'>eclampsia</z:hpo> 5.5%; <z:hpo ids='HP_0001622'>preterm deliveries</z:hpo> 22.22%; <z:hpo ids='HP_0001511'>intrauterine growth restriction</z:hpo> 11.11%; <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> 5.5%; <z:hpo ids='HP_0001562'>oligohydramnios</z:hpo> and <z:e sem="disease" ids="C0015930" disease_type="Disease or Syndrome" abbrv="">fetal distress</z:e> 16.6% </plain></SENT>
<SENT sid="4" pm="."><plain>There were no perinatal <z:hpo ids='HP_0011420'>deaths</z:hpo>, thrombotic events or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> flare </plain></SENT>
<SENT sid="5" pm="."><plain>Uterine artery PI was reduced and umbilical artery PI was &gt;95th percentile </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Plasmapheresis and low dose <z:chebi fb="0" ids="8382">prednisone</z:chebi> were associated with a low rate of obstetric and neonatal complications </plain></SENT>
<SENT sid="7" pm="."><plain>Plasmapheresis may be used to treat pregnant women with documented APS when first lines (aspirin and/or <z:chebi fb="5" ids="28304">heparin</z:chebi>) fail to prevent pregnancy loss </plain></SENT>
</text></document>